SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.

Animals Blood Glucose / metabolism Body Weight / drug effects CHO Cells Cricetulus Cyclopropanes / pharmacology Diabetes Mellitus, Experimental / blood Disease Models, Animal Dogs Eating / drug effects Glucagon-Like Peptide 1 / metabolism Humans Insulin Secretion / drug effects Islets of Langerhans / drug effects Male Mice Obesity / complications Piperidines / pharmacology Propionates / pharmacology Pyridines / pharmacology Rats Receptors, G-Protein-Coupled / agonists

Journal

The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362

Informations de publication

Date de publication:
08 2019
Historique:
received: 26 12 2018
accepted: 01 04 2019
pubmed: 12 6 2019
medline: 31 12 2019
entrez: 12 6 2019
Statut: ppublish

Résumé

The GPR40/FFA1 receptor is a G-protein-coupled receptor expressed in the pancreatic islets and enteroendocrine cells. Here, we report the pharmacological profiles of (3

Identifiants

DOI: 10.1124/jpet.118.255885 PMID: 31182471
pubmed: 31182471
pii: jpet.118.255885
doi: 10.1124/jpet.118.255885
doi:

Substances chimiques

Blood Glucose 0
Cyclopropanes 0
G-protein-coupled receptor 40, rat 0
Piperidines 0
Propionates 0
Pyridines 0
Receptors, G-Protein-Coupled 0
SCO-267 0
Glucagon-Like Peptide 1 89750-14-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

172-181

Informations de copyright

Copyright © 2019 The Author(s).

Auteurs

Hikaru Ueno (H)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).

Ryo Ito (R)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).

Shin-Ichi Abe (SI)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).

Mitsugi Ookawara (M)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).

Hirohisa Miyashita (H)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).

Hitomi Ogino (H)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).

Yasufumi Miyamoto (Y)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).

Tomoki Yoshihara (T)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).

Akihiro Kobayashi (A)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).

Yoshiyuki Tsujihata (Y)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).

Koji Takeuchi (K)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).

Masanori Watanabe (M)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).

Yukio Yamada (Y)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).

Tsuyoshi Maekawa (T)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).

Nobuhiro Nishigaki (N)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.) nobuhiro.nishigaki@takeda.com.

Yusuke Moritoh (Y)

Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.) yusuke.moritoh@scohia.com.
ORCID: 0000-0001-5252-6264

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Glucides › Sucres › Oses › Hexose › Glucose › Glycémie › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Mensurations corporelles › Poids › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules CHO › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Arvicolinae › Cricetinae › Cricetulus › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures alicycliques › Cyclopropanes › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Techniques d'investigation › Modèles animaux › Diabète expérimental › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Carnivora › Pinnipedia › Canidae › Chiens › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil buccodentaire et de l'appareil digestif › Phénomènes physiologiques de l'appareil digestif › Consommation alimentaire › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Hormones gastrointestinales › Peptides glucagon-like › Glucagon-like peptide 1 › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Phénomènes physiologiques › Sécrétion d'insuline › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Système endocrine › Glandes endocrines › Ilots pancréatiques › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Obésité › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipéridines › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Lipides › Acides gras › Acides gras volatils › Propionates › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › SCO-267, a GPR40 Full Agonist, Improves...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › SCO-267, a GPR40 Full Agonist, Improves...